Oruka Therapeutics (ORKA) Assets Average (2011 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Assets Average of $496.5 million for Q1 2026, up 28.45% year-over-year from $386.6 million in Q1 2025, and little changed quarter-over-quarter from $498.9 million in Q4 2025.
Oruka Therapeutics (ORKA) Assets Average (2011 - 2026) Analysis & Trends
Oruka Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $496.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 28.45% year-over-year to $496.5 million; the TTM figure through Mar 2026 stood at $496.5 million (up 28.45% YoY), while the FY2025 annual figure was $442.3 million, up 103.89% from the prior year.
- Assets Average for Q1 2026 stood at $496.5 million, roughly flat from $498.9 million in the prior quarter.
- The five-year high for Assets Average was $498.9 million in Q4 2025, with the low at $35.3 million in Q2 2024.
- The 5-year median for Assets Average is $49.6 million (2022), against an average of $190.6 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average decreased 26.32% in 2022, then soared 951.48% in 2024.
- Oruka Therapeutics' Assets Average stood at $44.0 million in 2022, then slipped by 12.5% to $38.5 million in 2023, then jumped by 951.48% to $405.1 million in 2024, then grew by 23.18% to $498.9 million in 2025, then decreased by 0.48% to $496.5 million in 2026.
- Business Quant data shows ORKA's Assets Average at $496.5 million in Q1 2026, $498.9 million in Q4 2025, and $433.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 821.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 821.94 Mn |
| Mar 31, 2026 | 496.55 Mn |
| Dec 31, 2025 | 498.93 Mn |
| Sep 30, 2025 | 433.33 Mn |
| Jun 30, 2025 | 367.27 Mn |
| Mar 31, 2025 | 386.57 Mn |
| Dec 31, 2024 | 405.05 Mn |
| Sep 30, 2024 | 223.97 Mn |
| Jun 30, 2024 | 35.28 Mn |
| Mar 31, 2024 | 37.28 Mn |
| Dec 31, 2023 | 38.52 Mn |
| Sep 30, 2023 | 40.13 Mn |
| Jun 30, 2023 | 41.57 Mn |
| Mar 31, 2023 | 42.57 Mn |
| Dec 31, 2022 | 44.03 Mn |
| Sep 30, 2022 | 46.53 Mn |
| Jun 30, 2022 | 49.56 Mn |
| Mar 31, 2022 | 52.97 Mn |
| Dec 31, 2021 | 57.56 Mn |
| Sep 30, 2021 | 62.77 Mn |